MX2020007842A - Anticuerpos anti-pd-l1 y usos de los mismos. - Google Patents
Anticuerpos anti-pd-l1 y usos de los mismos.Info
- Publication number
- MX2020007842A MX2020007842A MX2020007842A MX2020007842A MX2020007842A MX 2020007842 A MX2020007842 A MX 2020007842A MX 2020007842 A MX2020007842 A MX 2020007842A MX 2020007842 A MX2020007842 A MX 2020007842A MX 2020007842 A MX2020007842 A MX 2020007842A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- antibodies
- fragments
- cdr1
- cdr2
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 4
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan anticuerpos anti-PD-1 o fragmentos de los mismos. Los anticuerpos o fragmentos de los mismos se unen específicamente al dominio C de inmunoglobulina de la proteína PD-L1. En varios ejemplos, los anticuerpo o fragmentos de los mismos incluyen una VH CDR1 de la SEQ ID NO: 1, una VH CDR2 de la SEQ ID NO: 116, una VH CDR3 de la SEQ ID NO: 117, una VL CDR1 de la SEQ ID NO: 4, una VL CDR2 de la SEQ ID NO: 5, y una VL CDR3 de la SEQ ID NO: 6, o variantes de cada uno de los mismos. Se proporcionan métodos de uso de los anticuerpos o fragmentos de los mismos para tratar y diagnosticar enfermedades tales como cáncer y enfermedades infecciosas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018081079 | 2018-03-29 | ||
| PCT/CN2019/080458 WO2019185029A1 (en) | 2018-03-29 | 2019-03-29 | Anti-pd-l1 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007842A true MX2020007842A (es) | 2020-09-25 |
Family
ID=68060946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007842A MX2020007842A (es) | 2018-03-29 | 2019-03-29 | Anticuerpos anti-pd-l1 y usos de los mismos. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11220546B2 (es) |
| EP (1) | EP3589660A4 (es) |
| JP (1) | JP7124257B2 (es) |
| KR (2) | KR102475106B1 (es) |
| CN (1) | CN110891975B (es) |
| AU (1) | AU2019241339B2 (es) |
| BR (1) | BR112020019827A2 (es) |
| CA (1) | CA3086434C (es) |
| CL (1) | CL2020002223A1 (es) |
| EA (1) | EA202091590A1 (es) |
| IL (1) | IL275734B (es) |
| MX (1) | MX2020007842A (es) |
| MY (1) | MY188237A (es) |
| PE (1) | PE20210377A1 (es) |
| PH (1) | PH12020551173A1 (es) |
| SG (1) | SG11202006008WA (es) |
| UA (1) | UA125918C2 (es) |
| WO (1) | WO2019185029A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3325513A4 (en) * | 2016-06-13 | 2018-12-19 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| AU2019326635B2 (en) * | 2018-08-21 | 2024-05-23 | Abl Bio Inc. | Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof |
| WO2021097800A1 (en) * | 2019-11-22 | 2021-05-27 | Abl Bio Inc. | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof |
| WO2021219092A1 (en) * | 2020-04-30 | 2021-11-04 | I-Mab Biopharma Co., Ltd. | Pharmaceutical compositionscontaining anti-cd47 antibodies |
| IL299966A (en) * | 2020-07-28 | 2023-03-01 | Lepu Biopharma Co Ltd | Bifunctional molecules targeting PD-L1 and TGF- in the cell |
| MX2023001962A (es) | 2020-08-19 | 2023-04-26 | Xencor Inc | Composiciones anti-cd28. |
| CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
| CN114316045B (zh) | 2020-09-29 | 2024-07-12 | 英诺欧奇生物医药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| EP4276466A4 (en) * | 2021-01-08 | 2024-12-18 | Beijing Hanmi Pharmaceutical Co., Ltd. | ANTIBODY SPECIFICALLY BINDING WITH PD-L1 AND ANTIGEN-BINDING FRAGMENT OF ANTIBODY |
| CN115073599B (zh) * | 2021-03-16 | 2023-04-28 | 北京天广实生物技术股份有限公司 | 结合pd-l1的抗体及其用途 |
| KR20240166575A (ko) * | 2022-04-02 | 2024-11-26 | 하버 바이오메드 (상하이) 컴퍼니 리미티드 | Pd-l1 및 cd40을 표적화하는 항원 결합 단백질, 이의 제조 방법 및 응용 |
| WO2024104373A1 (en) * | 2022-11-15 | 2024-05-23 | I-Mab Biopharma Co., Ltd. | Anti-pd-l1 nanobodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103059138B (zh) * | 2005-05-09 | 2015-10-28 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| WO2011043194A1 (en) | 2009-10-09 | 2011-04-14 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device and method for manufacturing the same |
| US20170015758A1 (en) * | 2014-01-21 | 2017-01-19 | Medimmune, Llc | Compositions And Methods For Modulating And Redirecting Immune Responses |
| KR102130600B1 (ko) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Pd-l1 항체와 이를 이용한 치료 및 진단 |
| FI4141032T3 (fi) * | 2014-11-20 | 2024-07-31 | Hoffmann La Roche | T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| EP3325513A4 (en) * | 2016-06-13 | 2018-12-19 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
| CN107488229B (zh) * | 2016-06-13 | 2020-11-17 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
| CN108777906B (zh) | 2018-06-25 | 2020-06-16 | 珠海惠尔益电子科技有限公司 | 一种双灯组变焦电路及头灯 |
| WO2020020307A1 (en) * | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
-
2019
- 2019-03-29 SG SG11202006008WA patent/SG11202006008WA/en unknown
- 2019-03-29 AU AU2019241339A patent/AU2019241339B2/en active Active
- 2019-03-29 PE PE2020001301A patent/PE20210377A1/es unknown
- 2019-03-29 UA UAA202005634A patent/UA125918C2/uk unknown
- 2019-03-29 MY MYPI2020003980A patent/MY188237A/en unknown
- 2019-03-29 BR BR112020019827-7A patent/BR112020019827A2/pt unknown
- 2019-03-29 KR KR1020207032104A patent/KR102475106B1/ko active Active
- 2019-03-29 CA CA3086434A patent/CA3086434C/en active Active
- 2019-03-29 EA EA202091590A patent/EA202091590A1/ru unknown
- 2019-03-29 CN CN201980003429.7A patent/CN110891975B/zh active Active
- 2019-03-29 EP EP19769368.2A patent/EP3589660A4/en active Pending
- 2019-03-29 WO PCT/CN2019/080458 patent/WO2019185029A1/en active IP Right Grant
- 2019-03-29 JP JP2019553005A patent/JP7124257B2/ja active Active
- 2019-03-29 KR KR1020197031498A patent/KR102177931B1/ko active Active
- 2019-03-29 US US16/610,071 patent/US11220546B2/en active Active
- 2019-03-29 MX MX2020007842A patent/MX2020007842A/es unknown
-
2020
- 2020-06-29 IL IL275734A patent/IL275734B/en unknown
- 2020-08-02 PH PH12020551173A patent/PH12020551173A1/en unknown
- 2020-08-28 CL CL2020002223A patent/CL2020002223A1/es unknown
-
2021
- 2021-12-28 US US17/563,502 patent/US20220119531A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA202091590A1 (ru) | 2021-01-21 |
| WO2019185029A1 (en) | 2019-10-03 |
| US20200157222A1 (en) | 2020-05-21 |
| AU2019241339B2 (en) | 2021-08-12 |
| CN110891975B (zh) | 2023-11-10 |
| CL2020002223A1 (es) | 2021-01-29 |
| KR102475106B1 (ko) | 2022-12-08 |
| IL275734B (en) | 2022-06-01 |
| EP3589660A4 (en) | 2021-04-07 |
| KR102177931B1 (ko) | 2020-11-13 |
| IL275734A (en) | 2020-08-31 |
| BR112020019827A2 (pt) | 2021-01-05 |
| CA3086434A1 (en) | 2019-10-03 |
| UA125918C2 (uk) | 2022-07-06 |
| US20220119531A1 (en) | 2022-04-21 |
| AU2019241339A1 (en) | 2019-11-14 |
| MY188237A (en) | 2021-11-24 |
| KR20190128716A (ko) | 2019-11-18 |
| KR20200130747A (ko) | 2020-11-19 |
| CN110891975A (zh) | 2020-03-17 |
| NZ758371A (en) | 2024-10-25 |
| JP2020518233A (ja) | 2020-06-25 |
| EP3589660A1 (en) | 2020-01-08 |
| CA3086434C (en) | 2024-01-09 |
| PH12020551173A1 (en) | 2021-05-31 |
| US11220546B2 (en) | 2022-01-11 |
| PE20210377A1 (es) | 2021-03-02 |
| SG11202006008WA (en) | 2020-07-29 |
| JP7124257B2 (ja) | 2022-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| MY190771A (en) | Anti-pd-l1 antibodies and uses thereof | |
| MY200988A (en) | CD3 Binding Antibodies | |
| PH12019502785A1 (en) | Anti trbc1 antigen binding domains | |
| IL299221A (en) | CD3 binding antibodies | |
| PH12019550087A1 (en) | Anti-cd73 antibodies and uses thereof | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| IL265541B1 (en) | Bispecific antibodies and compositions comprising thereof for treating cancer | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| EP4435009A3 (en) | Claudin6 antibodies and methods of treating cancer | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| TW200720289A (en) | Antibodies against CCR5 and uses thereof | |
| NZ595235A (en) | Compositions and methods for increasing muscle growth | |
| JP2016533763A5 (ja) | ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物 | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| JP2017511152A5 (es) | ||
| MX2021004897A (es) | Anticuerpos pd-l1 humano. | |
| WO2020257789A3 (en) | Anti-tim-3 antibodies | |
| BR112017003138A2 (pt) | anticorpos anti-hepatite c e seus fragmentos de ligação ao antígeno |